We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » WHO PLAN TO EASE IP ENFORCEMENT MAY CHANGE LICENSING PRACTICES

WHO PLAN TO EASE IP ENFORCEMENT MAY CHANGE LICENSING PRACTICES

June 15, 2006

A World Health Organization (WHO) initiative to loosen diagnostics and drug intellectual property (IP) laws in developing countries could lead diagnostics manufacturers to consider patent restrictions for their products and dampen their financial incentive to develop tests for diseases that are prevalent in poorer nations, an industry consultant suggests.

A report issued in April by WHO's Commission on IP Rights, Innovation and Public Health encourages diagnostics and drug firms to avoid enforcing patents that would inhibit access to medical treatments. The report urges developed countries to grant voluntary licenses to poorer countries for use of their products and facilitate the transfer of medical technology to those countries.

Perhaps the biggest issue for companies in wealthier nations is the issue of compulsory licensing, which allows governments to force patent holders to grant use of their IP to the state or other entities.

One of the main problems with the current situation is that there seems to be no way to limit compulsory licenses to poorer countries alone, David Vogel, president of Intertech Engineering Associates and an expert on device development, safety and regulation, told FDAnews.

Compulsory licensing is meant to protect countries from inventors who may hold hostage potentially lifesaving technology by demanding unrealistic licensing fees, Vogel pointed out.

(http://www.fdanews.com/ddl/33_24/)

KEYWORDS FDAnews Device Daily Bulletin

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Consortium Gets EU Funding to Develop Continuous Blood Pressure Monitoring Device

  • FDA Approves GSK’s Oral Drug for Chronic Kidney Disease-Related Anemia

  • Aspivix’s Carevix Cleared to Reduce Pain, Bleeding in Gynecological Procedures

  • FDA Warns That Energy Supplement Contains Active Cialis Ingredient

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing